ZLTQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZLTQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ZELTIQ Aesthetics's enterprise value is $2,247.5 Mil. ZELTIQ Aesthetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2016 was $354.2 Mil. Therefore, ZELTIQ Aesthetics's EV-to-Revenue for today is 6.35.
The historical rank and industry rank for ZELTIQ Aesthetics's EV-to-Revenue or its related term are showing as below:
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-26), ZELTIQ Aesthetics's stock price is $56.48. ZELTIQ Aesthetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2016 was $8.73. Therefore, ZELTIQ Aesthetics's PS Ratio for today is 6.47.
The historical data trend for ZELTIQ Aesthetics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZELTIQ Aesthetics Annual Data | |||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 1.58 | 5.87 | 5.84 | 4.19 | 4.78 |
ZELTIQ Aesthetics Quarterly Data | ||||||||||||||||||||
Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | |
EV-to-Revenue | Get a 7-Day Free Trial | 4.19 | 3.84 | 3.51 | 4.59 | 4.78 |
For the Medical Devices subindustry, ZELTIQ Aesthetics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ZELTIQ Aesthetics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
ZELTIQ Aesthetics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 2247.490 | / | 354.201 | |
= | 6.35 |
ZELTIQ Aesthetics's current Enterprise Value is $2,247.5 Mil.
ZELTIQ Aesthetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $354.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZELTIQ Aesthetics (NAS:ZLTQ) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
ZELTIQ Aesthetics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 56.48 | / | 8.729 | |
= | 6.47 |
ZELTIQ Aesthetics's share price for today is $56.48.
ZELTIQ Aesthetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of ZELTIQ Aesthetics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd Erik Zavodnick | officer: President, International | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Bradley Hauser | officer: SVP, Research and Development | C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
Danika R Harrison | officer: SVP of Global Marketing | C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588 |
Mark J Foley | director, officer: President and CEO | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Taylor C. Harris | officer: SVP & Chief Financial Officer | 6035 STONERIDGE DRIVE, PLEASANTON CA 94588 |
Kevin C Oboyle | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Mary Fisher | director | C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
D Keith Grossman | director | |
Andrew N Schiff | director, 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Keith J Sullivan | officer: CCO, President, North America | C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043 |
Patrick F. Williams | officer: SVP & CFO | C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
Leonard C Debenedictis | officer: Chief Technical Officer | C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043 |
Bryan E Roberts | director | C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025 |
Jean George | director | CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421 |
Aisling Capital Iii Lp | 10 percent owner | 888 Seventh Avenue, 30th Fl, New York NY 10106 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.